- Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
- Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
- Kaerus Bioscience secures FDA approval for rare genetic disorder treatment
- Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
- Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing
- Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
- Donato Spota appointed as chief financial officer at Eleva
- Newron’s programme for treatment-resistant schizophrenia therapy approved
- Terumo’s plasma donation system adopted by Join Parachute to expand access to lifesaving therapies
- Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy
- Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
- Moderna expands use of AI-ready R&D platform
- European Commission approves Johnson & Johnson’s Crohn’s disease therapy
- Mind the gap: men’s health and the need for progress
- Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases